Gene · 6607
Papers3,510
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 3,510
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam. | J Neurol | 2024 | 38733387 | PubTator, text mining | PubMed |
| Transcriptome- and proteome-wide effects of a circular RNA encompassing four early exons of the spinal muscular atrophy genes. | Sci Rep | 2024 | 38714739 | PubTator, text mining | PubMed |
| CRISPR-dCas13d-based deep screening of proximal and distal splicing-regulatory elements. | Nat Commun | 2024 | 38714659 | PubTator, text mining | PubMed |
| Adherence and Persistence Among Risdiplam-Treated Individuals with Spinal Muscular Atrophy: A Retrospective Claims Analysis. | Adv Ther | 2024 | 38709394 | PubTator, text mining | PubMed |
| [Experience of the treatment of spinal muscular atrophy type 3 Kugelberg-Welander with Nusinersen]. | Zh Nevrol Psikhiatr Im S S Korsakova | 2024 | 38676690 | PubTator, text mining | PubMed |
| Considerations for Treatment in Clinical Care of Spinal Muscular Atrophy Patients. | Children (Basel) | 2024 | 38671712 | PubTator, text mining | PubMed |
| Early spinal muscular atrophy treatment following newborn screening: A 20-month review of the first Italian regional experience. | Ann Clin Transl Neurol | 2024 | 38600653 | PubTator, text mining | PubMed |
| Fatigue in Spinal Muscular Atrophy: a fundamental open issue. | Acta Myol | 2024 | 38586164 | PubTator, text mining | PubMed |
| The diversity of splicing modifiers acting on A-1 bulged 5'-splice sites reveals rules for rational drug design. | Nucleic Acids Res | 2024 | 38554107 | PubTator, text mining | PubMed |
| Carrier Screening and Diagnosis for Spinal Muscular Atrophy Using Droplet Digital PCR Versus MLPA: Analytical Validation and Early Test Outcome. | Genet Test Mol Biomarkers | 2024 | 38533877 | PubTator, text mining | PubMed |
| Incidental and secondary findings in trio exome sequencing. | Genes Dis | 2024 | 38523675 | PubTator, text mining | PubMed |
| Real-world evidence: Risdiplam in a patient with spinal muscular atrophy type I with a novel splicing mutation and one SMN2 copy. | Hum Mol Genet | 2024 | 38520738 | PubTator, text mining | PubMed |
| Feasibility and utility of in-home body weight support harness system use in young children treated for spinal muscular atrophy: A single-arm prospective cohort study. | PLoS One | 2024 | 38502672 | PubTator, text mining | PubMed |
| Diagnosis of Challenging Spinal Muscular Atrophy Cases with Long-Read Sequencing. | J Mol Diagn | 2024 | 38490302 | PubTator, text mining | PubMed |
| The impact of three SMN2 gene copies on clinical characteristics and effect of disease-modifying treatment in patients with spinal muscular atrophy: a systematic literature review. | Front Neurol | 2024 | 38487326 | PubTator, text mining | PubMed |
| [Risdiplam for the treatment of spinal muscular atrophy]. | Zh Nevrol Psikhiatr Im S S Korsakova | 2024 | 38465810 | PubTator, text mining | PubMed |
| Motor and neurocognitive profiles of children with symptomatic spinal muscular atrophy type 1 with two copies of SMN2 before and after treatment: a longitudinal observational study. | Front Neurol | 2024 | 38450080 | PubTator, text mining | PubMed |
| Advancing understanding and treatment of spinal muscular atrophy with four SMN2 copies: a critical review. | J Neurol | 2024 | 38436681 | PubTator, text mining | PubMed |
| Advances in machine-learning approaches to RNA-targeted drug design. | Artif Intell Chem | 2024 | 38434217 | PubTator, text mining | PubMed |
| Specificity, synergy, and mechanisms of splice-modifying drugs. | Nat Commun | 2024 | 38424098 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6607/papers?page=16